In SCLC, biomarkers of an improved outcome under immunotherapy in the CASPIAN phase 3 trial (NCT03043872) included gene signatures related to the antigen-presenting and processing machinery and MHC-I expression in patients treated with anti-PD-L1 and anti-CTLA424. The gene discussed is CD274; the disease is small cell lung carcinoma.